OncoMatch/Clinical Trials/NCT05783609
Epcoritamab and Rituximab for First-line Follicular Lymphoma
Is NCT05783609 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Epcoritamab and Rituximab for follicular lymphoma.
Treatment: Epcoritamab · Rituximab — The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma. The names of the study drugs involved in this study are: * Rituximab (a type of monoclonal antibody therapy) * Epcoritamab (a T-cell bispecific antibody)
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 overexpression (CD20+)
Histologically confirmed diagnosis of CD20+ FL
Disease stage
Excluded: Stage I
Grade: 123a (who)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic therapy
Exception: Prior treatment with radiation therapy or short course steroids is allowed
No prior systemic therapy for FL. Prior treatment with radiation therapy or short course steroids is allowed.
Cannot have received: CAR-T cell therapy
Treatment with CAR-T therapy within 100 days prior to first dose of epcoritamab.
Cannot have received: investigational drug
Treatment with an investigational drug within 4 weeks or 5 half-lives, whichever is longer, prior to the first dose of epcoritamab.
Cannot have received: chemotherapy and other non-investigational anti-neoplastic agents (except CD20 mAbs)
Chemotherapy and other non-investigational anti-neoplastic agents (except CD20 mAbs) within 4 weeks or 5 half-lives (whichever is shorter) prior to the first dose of epcoritamab.
Lab requirements
Blood counts
Absolute neutrophil count > 1.0x10^9/L unless due to marrow involvement by lymphoma in which case ANC must be >0.5x10^9/L; Platelets > 75 x10^9/L, unless due to marrow involvement by lymphoma, in which case platelets must be >50 x10^9/L
Kidney function
Estimated CrCl (Cockcroft Gault) ≥ 45ml/min
Liver function
Total bilirubin < 1.5 X ULN, unless Gilbert syndrome, in which case direct bilirubin must be < 1.5 x ULN; AST/ALT < 2.5 X ULN, unless documented liver involvement by lymphoma, in which case AST/ALT must be <5 x ULN
Adequate hematologic and organ function: 1. Absolute neutrophil count > 1.0x10^9/L unless due to marrow involvement by lymphoma in which case ANC must be >0.5x10^9/L 2. Platelets > 75 x10^9/L, unless due to marrow involvement by lymphoma, in which case platelets must be >50 x10^9/L 3. Estimated CrCl (Cockcroft Gault) ≥ 45ml/min 4. Total bilirubin < 1.5 X ULN, unless Gilbert syndrome, in which case direct bilirubin must be < 1.5 x ULN 5. AST/ALT < 2.5 X ULN, unless documented liver involvement by lymphoma, in which case AST/ALT must be <5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Beth Israel Deaconess Medical Center · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
- University of Rochester Medical Center · Rochester, New York
- The Ohio State University Wexner Medical Center · Columbus, Ohio
- Medical College of Wisconsin · Milwaukee, Wisconsin
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify